Call for Abstracts

Dear abstract authors,

We are very pleased you are interested in submitting your research abstract to the 2022 American Society of Hematology meeting -- the premier global meeting in hematology -- being held in New Orleans, December 10-13, 2022. Before you begin the process, I would like to highlight several changes in our abstract format and in abstract categories and give you more information regarding requirements for presentation of abstracts at the annual meeting. Your close attention is necessary to give your abstract the best chance for inclusion in the annual meeting as an oral session presentation or poster.

• Abstracts will be limited to 3,800 characters to be accommodated on our digital platform.
• Abstracts may include no more than two panels of additional content. A "panel" would be defined as a table or a single graphical representation of data (ie equivalent to a figure panel in a paper, not to a multi-panel figure).

Please carefully review all descriptions before selecting a category for your abstract. Categories are updated every year to respond to submission trends and to encompass new topics. This year, updates have been made to multiple category descriptions with significant changes as follows:

• The 300s Categories (Hemostasis, Thrombosis and Vascular Biology) have all been reorganized, with inclusion of basic/translational studies of thrombosis in category 301, and clinical and epidemiologic aspects of thrombotic microangiopathies and of COVID-19 in category 331, among other changes.
• Category 506 (Bone Marrow Microenvironment), now encompasses interactions of the microenvironment with both normal and leukemia stem cells.
• Category 508 has been split into 508 (Bone Marrow Failure: Acquired) and 509 (Bone Marrow Failure and Cancer Predisposition Syndromes: Inherited).
• Categories 602 and 603 have been reorganized around lineage targets rather than oncogenic mechanism, and now consist of 602 (Myeloid Oncogenesis: Basic) and 603 (Lymphoid Oncogenesis: Basic).
• Category 704 has been split into 704 (Cellular Immunotherapies: Early Phase Clinical Trials) and 705 (705 Late Phase and Commercially Available Therapies).

Note that ASH reserves the right to move your abstract to a more appropriate category if misplacement is noted by the Secretary during abstract processing; however, correct categorization at the time of submission is the author's responsibility and will ensure the highest quality review process.

ASH plans to hold a hybrid in-person/virtual meeting at ASH 2022 in New Orleans. However ASH requires that abstract presenters of oral or poster presentations attend the meeting and present their abstract and respond to questions in person. If the first author is unable to attend in person, another abstract author able to attend in person may be substituted as the presenter. We realize decisions about attendance may not be feasible before the abstract submission deadline and we will accommodate necessary changes as needed. ASH is continually re-assessing the status of our upcoming meetings in light of the COVID-19 pandemic. We encourage you to monitor our annual meeting webpages to stay abreast of the latest updates. Public health guidance on preventing the transmission of COVID-19 continues to evolve, and ASH will, at minimum, base its on-site protocols on the latest guidance from the CDC in addition to local regulations in New Orleans.

• Due to the uncertain nature of the ongoing COVID-19 pandemic and technical complexities of presenting a hybrid in-person/virtual meeting, we also require that you submit a pre-recorded version of your presentation by November 16 as an emergency back-up should it become necessary to pivot to the recording due to circumstances beyond ASH's control.
• ASH reminds authors that the last date to withdraw abstracts from the annual meeting is September 16, 2022.

The link to our submission process is provided here for ease of access. For questions about the abstract submission process, contact ashabstracts@hematology.org.

We look forward seeing you in New Orleans and hearing about your current research in hematology!

Sincerely,

Cynthia Dunbar, MD
ASH Secretary

Please Note: - Pre-recorded presentations for both oral and poster presentations are required by November 16th.
 
Presentation length for an oral presentation is 10-minutes with 5 minutes for Q&A.
 
Poster presentations will consist of 3-5 minute recordings accompanying a slide deck on the virtual platform. Printed posters will be hung in the poster hall for those attending in-person, and the poster images will also be available on the virtual platform.
 
Failure to submit a presentation by November 16th will result in removal of presenting privileges, to be noted by "Presentation Not Available" in meeting materials.

Eligibility

To submit an abstract, the following criteria must be met

• At least one of the authors must be an ASH member, who has paid the current membership dues.

  If none of the abstract authors is an ASH member, the abstract must be sponsored by a current ASH member or it will not be reviewed. ASH members are urged to use their judgment in restricting sponsorship to a reasonable number of abstracts, keeping in mind that they are endorsing the authenticity and quality of each abstract that they sponsor.

• Research and/or studies must fit into one of the ASH 2022 Abstract Review Categories.
• Updated analyses will be considered only if the abstract is a significant extension of previously published work. The author must provide an explanation to show how the abstract contains significant new information.

  *Note: Abstracts submitted to other ASH meetings (e.g., the 2019 Meetings on Lymphoma and Hematologic Malignancies) are exempted from the above meeting-size restriction and are eligible to be re-submitted to the 2022 ASH Annual Meeting.

Any of the following criteria will make an abstract ineligible for presentation at the ASH annual meeting

• Data from peer-reviewed content publicly available via major search engines (such as PubMed, Google Scholar, etc.,)
• Data are accepted for journal publication before the abstract submission closing date.
• Data have been or are to be presented at a meeting of 1,000 or more participants before January 1, 2022.*
• Data are to be presented at an ASH Friday Satellite Symposium, scheduled for December 9, 2022.

Please note: Abstracts accepted for or presented as part of a meeting of any size (in-person or virtual) since January 1, 2022, are eligible for submission for ASH 2022, provided they meet the above eligibility criteria. By submitting a previously published abstract, submitters grant ASH permission to display the abstract in the meeting mobile app and online program. Submitters are responsible for obtaining this permission from the copyright holder. Previously published abstracts will not be published in Blood; they will only be displayed digitally in non-enduring meeting materials.

Responsibilities of the Presenting Author

• The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the "Contact Information" section of the online abstract submission system.
• The presenting author must be one of the co-authors listed on the submitted abstract.
• In contrast to past years, oral abstract and poster presentations will no longer be contained in the ACCME-accredited portion of the annual meeting. Therefore, presenting authors are no longer subject to ACCME restrictions, and can be employees of publicly-traded or privately-held healthcare companies or owners of privately-held entities. All relevant conflicts of interest must be disclosed, and data presented fairly and transparently.
   
  Presenting authors are expected to be on-site in New Orleans. The presenter can be changed on the Author(s) step until the August 2 deadline. More information is available here.
• The presenting author is responsible for the following:
• Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
• Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ASH.
• Obtaining all the conflict of interest disclosure and copyright transfer information from co-authors.
• Forwarding all correspondence to all co-authors, including the ASH policies and guidelines, and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support for Continuing Medical Education (CME).

Technical Requirements

The electronic submission system is compatible with PC Windows and Apple computers and with most browsers, including Google Chrome, Mozilla Firefox, Internet Explorer, Safari, and Netscape.

Before you Begin

Have the following information available:

Submission Process

FAQS

Please consider the following before submitting your abstract to the ASH Annual Meeting:

• Q: What is the submission deadline for the abstracts?

  A: The deadline for all abstracts is at 11:59 p.m. PDT. Submissions that are incomplete at this time will be rejected without review.

• Q: Can I still submit an abstract if I presented it at another scientific meeting or submitted it to a journal?

  A: Any of the following criteria will make an abstract ineligible for presentation at the ASH annual meeting:

  • Data from peer-reviewed content publicly available via major search engines (such as PubMed, Google Scholar, etc.),
  • Data are accepted for journal publication before the abstract submission closing date.
  • Data have been or are to be presented at a meeting of 1,000 or more participants before the 2022 ASH annual meeting.
  • Data are to be presented at an ASH Friday Satellite Symposium, scheduled for December 9, 2022.

  Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown. In this case, please use the Updated Analyses section of the abstract form to explain the significance of the new data. The reviewers will have this information available during their evaluation.

  *Note: Abstracts submitted to other ASH meetings (e.g., the 2019 Meetings on Lymphoma and Hematologic Malignancies) are exempted from the above meeting-size restriction and are eligible to be re-submitted to the 2022 ASH Annual Meeting.

• Q: How long can the abstracts be?

  A: The abstracts are limited to a maximum of 3,800 characters. Note that this character count does not include spaces. Figures are not included in the character count.

• Q: May I include tables in my abstract?

  A: Yes, but we now ask that any tables that you wish to include must be uploaded as an image. You will not be allowed to paste a table directly into the text of the abstract, but rather you must include it as an image in the appropriate place and use the Upload method. To convert a table to an image, we recommend taking a screenshot of the table. If using a PC, use the Snipping Tool or the Print Screen button. If using a Mac, press Command-Shift-4.

• Q: If I have images in my abstract, what resolution should my images be?

  A: We require a minimum of 300 dpi for all uploaded images. This will insure proper resolution for display.

• Q: How many abstracts can a single author submit?

  A: There is no set limit as to the number of abstracts a single author can submit.

• Q: How many authors can contribute to a single abstract?

  A: There is no set limit to the number of authors who can contribute to a single abstract.

• Q: Do all authors on an abstract have to submit their Conflict-of-Interest disclosures to ASH? How should they do that?

  A: The submitting author must manually enter disclosure information for all authors into the online abstract submission form. Authors must disclose all relationships they may have, regardless of their relevance to an abstract. If an author's COI disclosure form populates with information already supplied, we strongly urge you to use this existing information for that person. If you are aware of a relationship that should be added to that disclosure, you may do so, and the update will be applied all of that individual's disclosures for the entire meeting. Please do NOT delete any existing disclosure information if you are not the person in question. You may wish to use this sample form to collect disclosure information from your coauthors. (Please note that this form should NOT be sent to ASH; you are responsible for entering the information on the form into the online abstract submission system for every author.)

• Q: What if I am not able to submit my abstract at this time?

  A: ASH allows for the submission of late-breaking abstracts, covering ground-breaking research results that were not available by the regular submission deadline. Please note that only six late-breaking abstracts will be accepted for presentation, regardless of how many are submitted. Late-breaking Abstracts may be submitted between October 17 and October 27, 2022.

• Q: What if I need to withdraw my abstract?

  A: The deadline to withdraw an abstract is September 16, 2022. Abstracts cannot be withdrawn after this deadline, and will appear in all meeting publications and in the abstracts issue of Blood.

• Q: When will I know if my abstract has been accepted?

  A: You will receive an e-mail in early-October notifying you if your abstract has been accepted and whether you are invited to present it at the Annual Meeting.

• Q: When will my accepted abstract be published?

  A: Abstracts that are accepted for presentation will be made available online in early November on the ASH annual meeting Program Web site. They will also be published in a mid-November issue of Blood.